Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness
- PMID: 19945340
- DOI: 10.1016/j.sleep.2009.07.012
Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness
Abstract
Objective: Two doses of EVT 201, a partial positive allosteric modulator of the GABA(A) system, were evaluated in elderly primary insomnia patients with daytime sleepiness.
Patients and methods: Participants were 149 elderly patients with DSM-IV primary insomnia including evidence of daytime sleepiness (53 males, 96 females; mean age 71.3yrs, range 65-86yrs). A randomized, multicentre, double-blind, placebo-controlled, parallel-group design was used to assess the hypnotic efficacy of EVT 201 1.5 and 2.5mg during seven consecutive nights. Polysomnography (PSG) was performed on nights 1, 6 and 7 of treatment. Daytime assessments on Day 8 included the multiple sleep latency test (MSLT), Rey Auditory Verbal Learning Test (RAVLT), Psychomotor Vigilance Task (PVT) and the Karolinska Sleepiness Scale (KSS). The primary endpoint was total sleep time (TST) and the key secondary endpoint was mean MSLT latency.
Results: Compared to placebo, EVT 201 1.5 and 2.5mg increased TST (30.9, 56.4min, respectively; p=0.0001, p<0.0001); reduced wake after sleep onset (WASO; -15.2, -36.1min, respectively; p=0.014, p<0.0001); reduced latency to persistent sleep (LPS; -15.9, -19.9min, respectively; p=0.009, p=0.001). The 2.5mg dose also reduced WASO in hours 5-8 (-16.3min, p=0.001). Both doses also improved subjective sleep quality and usual subjective efficacy measures. A significantly longer mean MSLT latency was observed on Day 8 with both doses, compared to placebo (2min increase; p=0.03, both doses). The PVT, RAVLT, and POMS did not differ among treatment groups. No serious or unexpected treatment emergent adverse events were noted.
Conclusion: EVT 201 improved PSG measures of sleep onset and sleep maintenance and significantly reduced daytime physiological sleep tendency. These findings suggest that treatment of primary insomnia in older patients has the potential to improve daytime sleepiness as well as sleep.
Copyright 2009 Elsevier B.V. All rights reserved.
Comment in
-
The pit (of sleeplessness) and the pendulum (of regulation).Sleep Med. 2010 Jan;11(1):7-8. doi: 10.1016/j.sleep.2009.08.002. Epub 2009 Nov 28. Sleep Med. 2010. PMID: 19945339 No abstract available.
Similar articles
-
The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.Sleep Med. 2009 Sep;10(8):859-64. doi: 10.1016/j.sleep.2008.10.005. Epub 2009 Mar 31. Sleep Med. 2009. PMID: 19345644 Clinical Trial.
-
A polysomnography study of eszopiclone in elderly patients with insomnia.Curr Med Res Opin. 2006 Sep;22(9):1633-42. doi: 10.1185/030079906X112741. Curr Med Res Opin. 2006. PMID: 16968566 Clinical Trial.
-
Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.Sleep Med. 2006 Aug;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008. Epub 2006 Jul 3. Sleep Med. 2006. PMID: 16815744 Clinical Trial.
-
Ramelteon for the treatment of insomnia.Clin Ther. 2006 Oct;28(10):1540-55. doi: 10.1016/j.clinthera.2006.10.016. Clin Ther. 2006. PMID: 17157111 Review.
-
[Development of compounds active in insomnia: recent developments and methodological aspects].Rev Neurol (Paris). 2003 Nov;159(11 Suppl):6S48-55. Rev Neurol (Paris). 2003. PMID: 14646800 Review. French.
Cited by
-
Dimdazenil: First Approval.Drugs. 2024 May;84(5):607-611. doi: 10.1007/s40265-024-02020-9. Epub 2024 Mar 28. Drugs. 2024. PMID: 38546956 Review.
-
Effect of Placebo Conditions on Polysomnographic Parameters in Primary Insomnia: A Meta-Analysis.Sleep. 2015 Jun 1;38(6):925-31. doi: 10.5665/sleep.4742. Sleep. 2015. PMID: 25515108 Free PMC article.
-
Sensitivity and specificity of polysomnographic criteria for defining insomnia.J Clin Sleep Med. 2013 May 15;9(5):481-91. doi: 10.5664/jcsm.2672. J Clin Sleep Med. 2013. PMID: 23674940 Free PMC article.
-
The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.Drugs. 2023 May;83(7):587-619. doi: 10.1007/s40265-023-01859-8. Epub 2023 Mar 22. Drugs. 2023. PMID: 36947394
-
Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis.Neurol Sci. 2025 Mar;46(3):1179-1190. doi: 10.1007/s10072-024-07872-3. Epub 2024 Nov 13. Neurol Sci. 2025. PMID: 39535582
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical